📢 **Healthy Competition: The Real Solution for Affordable Medicines** Today's announcement from CMS on price setting for a select few brand-name drugs might seem like progress, but the projected 22% savings can't compete with the benefits that generics and biosimilars bring to patients and the U.S. healthcare system. Generics and biosimilars drive down costs far more effectively, ensuring that patients have access to life-saving medications at a fraction of the price. The uncertainty created by current policies threatens this competition, ultimately hurting patients who rely on affordable options. The Association for Accessible Medicines, is urging policymakers to focus on removing barriers like patent thickets and PBM brand drug rebates, which delay access to these essential medicines. Let's prioritize healthy competition and proven solutions over ineffective price controls. #Healthcare #Pharma #Generics #Biosimilars #Policy #AffordableCare
The benefit projected by the new CMS price setting does not compare to the benefit of generic and biosimilar medicines. The tens of millions of Americans who trusted their health to generics and biosimilars in 2022 saved $408 billion – and more than $2.9 trillion in the last decade! Read our Interim President & CEO David Gaugh 's full response to the recent U.S. Department of Health and Human Services announcement, aiming to identify cost savings related to negotiated pricing for brand drugs: https://lnkd.in/e94yGX_h Biosimilars Council #healthcare #rx
